Cat. No.: HY-B0011

Docetaxel

Name: Docetaxel
Brand: MedChemExpress
SKU: HY-B0011
Price: 72.00 USD
Availability: InStock
Rating: 5 (183 reviews)

(Synonyms: RP-56976)

183 Cited Publications

Avis client

Based on 183 publication(s) in Google Scholar

Docetaxel (RP-56976) is an orally active tubulin stabilizer with antitumor activity. Docetaxel is a P-glycoprotein substrate and is metabolized by CYP3A to inactive products. Docetaxel binds tubulin, promotes tubulin polymerization, and inhibits microtubule depolymerization. Docetaxel induces aberrant mitosis followed by necrotic-like cell death at low concentrations, and induces G2/M mitotic arrest and drives apoptosis at high concentrations. Docetaxel induces renal injury/renal alterations, sex-dependent granule toxicity/uptake, low cardiac delivery, and decreased hepatic SOD/increased catalase/hepatotoxicity. Docetaxel can be used in cancer-related research.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté : 99.94%
CAS No.: 114977-28-5
Formule: C₄₃H₅₃NO₁₄
Masse moléculaire:807.88

Stockage:

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Docetaxel Chemical Structure

CAS No.: 114977-28-5

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (183)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

^[1]

CYP3A

Voir tous les produits spécifiques à Isoform Cytochrome P450 :

Cellular Effect

Cell Line	Type	Value	Description	References
1A9	IC₅₀	3.55 nM Compound: 8	Cytotoxicity against human 1A9 cells Cytotoxicity against human 1A9 cells	[PMID: 28850227]
A2780	IC₅₀	11.2 nM Compound: 1b	Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 29359935]
A2780	IC₅₀	2.9 nM Compound: 1b	Antiproliferative activity against human A2780 cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell viability by MTT assay	[PMID: 37490800]
A2780	IC₅₀	3 nM Compound: Docetaxel	Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38294341]
A-375	IC₅₀	4.5 nM Compound: DT	Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
A-427	GI₅₀	4.4 nM Compound: Docetaxel	Growth inhibition of human A-427 cells measured after 72 to 96 hrs by cell-titer glo assay Growth inhibition of human A-427 cells measured after 72 to 96 hrs by cell-titer glo assay	[PMID: 39102508]
A549	IC₅₀	3.41 μM Compound: DTX	Cytotoxicity against human A-549 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control Cytotoxicity against human A-549 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control	[PMID: 26791014]
A549	IC₅₀	734 nM Compound: Docetaxel	Cytotoxicity against human paclitaxl resistant A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human paclitaxl resistant A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 30036834]
A549	IC₅₀	9.8 nM Compound: Docetaxel	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 30036834]
A549	IC₅₀	19.5 nM Compound: Docetaxel	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 34058663]
A549	IC₅₀	18 nM Compound: Docetaxel	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38294341]
A549/TR	IC₅₀	836.2 nM Compound: Docetaxel	Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 34058663]
BT-474	IC₅₀	21.4 nM Compound: DT	Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
CAKI-1	IC₅₀	2.7 nM Compound: DT	Antiproliferative activity against human CAKI-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human CAKI-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
Calu-1	IC₅₀	0.4 nM Compound: Docetaxel	Antiproliferative activity against human Calu1 cells after 72 hrs by MTT assay Antiproliferative activity against human Calu1 cells after 72 hrs by MTT assay	[PMID: 30629433]
CAPAN-1	IC₅₀	0.95 μM Compound: Docetaxel	Cytostatic activity against human Capan1 cells Cytostatic activity against human Capan1 cells	[PMID: 30738653]
CAPAN-1	IC₅₀	0.019 μM Compound: Docetaxel	Antiproliferative activity against human Capan1 cells Antiproliferative activity against human Capan1 cells	[PMID: 31005446]
CAPAN-1	IC₅₀	0.025 μM Compound: Docetaxel	Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
CAPAN-1	IC₅₀	0.0088 μM Compound: Docetaxel	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
CCD-18Co	IC₅₀	116.54 μM Compound: DTX	Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32203786]
CWR22R	GI₅₀	6 ng/mL Compound: Dxtl	Growth inhibition of human 22Rv1 cells incubated for 48 hrs by MTS assay Growth inhibition of human 22Rv1 cells incubated for 48 hrs by MTS assay	[PMID: 31767266]
CWR22R	IC₅₀	2.1 nM Compound: DTX	Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability	[PMID: 34464875]
CWR22R	CC₅₀	1 nM Compound: Docetaxel	Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34717125]
CWR22R	CC₅₀	3.3 nM Compound: Docetaxel	Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay	[PMID: 34797052]
DU-145	IC₅₀	0.026 μM Compound: Docetaxel	Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 24 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 27077446]
DU-145	CC₅₀	0.81 μM Compound: Docetaxel	Cytotoxic activity in human DU145 cells by sulforhodamine B assay Cytotoxic activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
DU-145	IC₅₀	0.01 μM Compound: Docetaxel	Antiproliferative activity in human DU145 cells by sulforhodamine B assay Antiproliferative activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
DU-145	IC₅₀	0.1 nM Compound: Docetaxel	Cytotoxicity against human DU145 cells after 72 hrs by MTS assay Cytotoxicity against human DU145 cells after 72 hrs by MTS assay	[PMID: 29406710]
DU-145	IC₅₀	0.0012 μM Compound: Docetaxel	Antiproliferative activity against docetaxel-sensitive human DU145 cells after 3 days by WST-1 assay Antiproliferative activity against docetaxel-sensitive human DU145 cells after 3 days by WST-1 assay	[PMID: 29784275]
DU-145	IC₅₀	0.1 nM Compound: Docetaxel	Antiproliferative activity against human DU145 cells Antiproliferative activity against human DU145 cells	[PMID: 31251599]
DU-145	IC₅₀	4.95 nM Compound: Docetaxel	Cytotoxicity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31945665]
DU-145	IC₅₀	43.25 nM Compound: Docetaxel	Cytotoxicity against human DU-145 cells over expressing CYP1B1 assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human DU-145 cells over expressing CYP1B1 assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31945665]
DU-145	IC₅₀	0.0012 μM Compound: Docetaxel	Antiproliferative activity against androgen-insensitive human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay Antiproliferative activity against androgen-insensitive human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay	[PMID: 33753258]
DU-145	IC₅₀	8.58 μM Compound: Docetaxel	Antiproliferative activity against Docetaxel-resistant human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay Antiproliferative activity against Docetaxel-resistant human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay	[PMID: 33753258]
DU-145	IC₅₀	5 nM Compound: Docetaxel	Cytotoxicity against human DU-145 cells Cytotoxicity against human DU-145 cells	[PMID: 33951490]
DU-145	IC₅₀	5 μg/mL Compound: Docetaxel	Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth by MTT assay	[PMID: 34000484]
DU-145	EC₅₀	6.05 nM Compound: Docetaxel	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability by MTT assay	[PMID: 37290495]
DU-145	IC₅₀	0.04 μM Compound: PC	Cytotoxicity against human DU-145 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human DU-145 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 39102454]
DU-145	IC₅₀	5.4 μM Compound: Docetaxel	Cytotoxicity against human DU-145 cells assessed as cell death measured by MTT assay Cytotoxicity against human DU-145 cells assessed as cell death measured by MTT assay	[PMID: 39137365]
HCT-116	IC₅₀	129.8 nM Compound: Docetaxel	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 28972762]
HCT-116	IC₅₀	0.004 μM Compound: Docetaxel	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 31005446]
HCT-116	IC₅₀	3.5 nM Compound: DTX	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32203786]
HCT-116	IC₅₀	3.5 x 10^-3 μM Compound: DTX	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32203786]
HCT-116	IC₅₀	0.007 μM Compound: Docetaxel	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
HCT-116	IC₅₀	4 nM Compound: Docetaxel	Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33221063]
HCT-116	IC₅₀	0.0017 μM Compound: Docetaxel	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
HEK293	CC₅₀	1.6 μM Compound: Docetaxel	Cytotoxic activity in HEK293 cells by sulforhodamine B assay Cytotoxic activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HEK293	IC₅₀	0.11 μM Compound: Docetaxel	Antiproliferative activity in HEK293 cells by sulforhodamine B assay Antiproliferative activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HEK293	IC₅₀	19.7 μM Compound: DTX	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32203786]
HEK293	IC₅₀	7.5 nM Compound: DT	Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
HeLa	IC₅₀	3.23 μM Compound: DTX	Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control	[PMID: 26791014]
HeLa	IC₅₀	0.061 μM Compound: Docetaxel	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 27077446]
HeLa	IC₅₀	13 μM Compound: Docetaxel	Growth inhibition of human HeLa cells over expressing beta3-tubulin measured after 96 hrs by sulforhodamine B assay Growth inhibition of human HeLa cells over expressing beta3-tubulin measured after 96 hrs by sulforhodamine B assay	[PMID: 27894589]
HeLa	IC₅₀	4 μM Compound: Docetaxel	Growth inhibition of human HeLa cells measured after 96 hrs by sulforhodamine B assay Growth inhibition of human HeLa cells measured after 96 hrs by sulforhodamine B assay	[PMID: 27894589]
HeLa	CC₅₀	0.09 μM Compound: Docetaxel	Cytotoxic activity in human HeLa cells by sulforhodamine B assay Cytotoxic activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	IC₅₀	0.07 μM Compound: Docetaxel	Antiproliferative activity in human HeLa cells by sulforhodamine B assay Antiproliferative activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	IC₅₀	3.5 nM Compound: 1b	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 29359935]
HeLa	IC₅₀	0.3 nM Compound: Docetaxel	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30629433]
HeLa	IC₅₀	0.68 μM Compound: Docetaxel	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay	[PMID: 36126331]
HeLa	IC₅₀	0.7 nM Compound: 1b	Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability by MTT assay	[PMID: 37490800]
HeLa	IC₅₀	13 nM Compound: 1b	Antiproliferative activity against human HeLa cells overexpressing betaIII-tubulin assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human HeLa cells overexpressing betaIII-tubulin assessed as inhibition of cell viability by MTT assay	[PMID: 37490800]
HeLa	IC₅₀	0.7 nM Compound: Docetaxel	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38294341]
HeLa	IC₅₀	13 nM Compound: Docetaxel	Antiproliferative activity against human HeLa cells expressing tubulin betaIII assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells expressing tubulin betaIII assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38294341]
HeLa	IC₅₀	1 nM Compound: DT	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
HEp-2	CC₅₀	0.06 μM Compound: Docetaxel	Cytotoxic activity in human Hep2 cells by sulforhodamine B assay Cytotoxic activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
HEp-2	IC₅₀	0.06 μM Compound: Docetaxel	Antiproliferative activity in human Hep2 cells by sulforhodamine B assay Antiproliferative activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
HepG2	IC₅₀	2.86 μM Compound: DTX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control	[PMID: 26791014]
HepG2	IC₅₀	8.3 μM Compound: Docetaxel	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27617953]
HEY	IC₅₀	0.86 μM Compound: Taxotere	Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay	[PMID: 29517223]
HL-60	IC₅₀	1.94 μM Compound: Docetaxel	Cytostatic activity against human HL60 cells Cytostatic activity against human HL60 cells	[PMID: 30738653]
HL-60	IC₅₀	0.047 μM Compound: Docetaxel	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 31005446]
HL-60	IC₅₀	0.05 μM Compound: Docetaxel	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
HL-60	IC₅₀	0.0072 μM Compound: Docetaxel	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
HT-1080	IC₅₀	1.5 nM Compound: DT	Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
K562	IC₅₀	0.039 μM Compound: Docetaxel	Cytotoxicity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 27077446]
K562	IC₅₀	3 μM Compound: Docetaxel	Cytostatic activity against human K562 cells Cytostatic activity against human K562 cells	[PMID: 30738653]
K562	IC₅₀	0.016 μM Compound: Docetaxel	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 31005446]
K562	IC₅₀	0.009 μM Compound: Docetaxel	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
K562	IC₅₀	0.0152 μM Compound: Docetaxel	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
KB	GI₅₀	0.13 nM Compound: Docetaxel	Growth inhibition of human KB cells after 72 hrs by MTS assay Growth inhibition of human KB cells after 72 hrs by MTS assay	[PMID: 26778612]
KB	CC₅₀	0.18 μM Compound: Docetaxel	Cytotoxic activity in human KB cells by sulforhodamine B assay Cytotoxic activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
KB	IC₅₀	0.05 μM Compound: Docetaxel	Antiproliferative activity in human KB cells by sulforhodamine B assay Antiproliferative activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
KB	IC₅₀	7.3 nM Compound: Docetaxel	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 30036834]
KB	IC₅₀	38 nM Compound: Docetaxel	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 30407813]
KB	IC₅₀	17.5 nM Compound: Docetaxel	Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 34058663]
L132	IC₅₀	1.68 μM Compound: DTX	Cytotoxicity against human L-132 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control Cytotoxicity against human L-132 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control	[PMID: 26791014]
LN-229	IC₅₀	0.002 μM Compound: Docetaxel	Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
LNCaP	IC₅₀	0.0002 μM Compound: Docetaxel	Antiproliferative activity against docetaxel-sensitive human LNCAP cells after 3 days by WST-1 assay Antiproliferative activity against docetaxel-sensitive human LNCAP cells after 3 days by WST-1 assay	[PMID: 29784275]
LNCaP	IC₅₀	0.2 nM Compound: Docetaxel	Antiproliferative activity against docetaxel-sensitive human LNCAP cells after 3 days by WST-1 assay Antiproliferative activity against docetaxel-sensitive human LNCAP cells after 3 days by WST-1 assay	[PMID: 29784275]
LNCaP	IC₅₀	0.0002 μM Compound: Docetaxel	Antiproliferative activity against androgen-insensitive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay Antiproliferative activity against androgen-insensitive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay	[PMID: 33753258]
LNCaP	IC₅₀	0.2 nM Compound: Docetaxel	Antiproliferative activity against androgen-insensitive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay Antiproliferative activity against androgen-insensitive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay	[PMID: 33753258]
LNCaP	IC₅₀	1 nM Compound: DTX	Cytotoxicity against human LNCaP cells assessed as reduction in cell viability Cytotoxicity against human LNCaP cells assessed as reduction in cell viability	[PMID: 34464875]
LNCaP	IC₅₀	12.3 μM Compound: Docetaxel	Cytotoxicity against human LNCaP cells assessed as cell death measured by MTT assay Cytotoxicity against human LNCaP cells assessed as cell death measured by MTT assay	[PMID: 39137365]
MCF7	IC₅₀	3.6 μM Compound: DTX	Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control	[PMID: 26791014]
MCF7	IC₅₀	0.022 μM Compound: Docetaxel	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 27077446]
MCF7	IC₅₀	0.8 μM Compound: Docetaxel	Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay	[PMID: 27240278]
MCF7	CC₅₀	0.01 μM Compound: Docetaxel	Cytotoxic activity in human MCF7 cells by sulforhodamine B assay Cytotoxic activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MCF7	IC₅₀	0.01 μM Compound: Docetaxel	Antiproliferative activity in human MCF7 cells by sulforhodamine B assay Antiproliferative activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MCF7	IC₅₀	1.7 nM Compound: Docetaxel	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 30036834]
MCF7	IC₅₀	10.3 nM Compound: Docetaxel	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 30407813]
MCF7	IC₅₀	0.5 nM Compound: Docetaxel	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30629433]
MCF7	IC₅₀	3.9 nM Compound: DT	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
MDA-MB-231	IC₅₀	0.032 μM Compound: Docetaxel	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 27077446]
MDA-MB-231	CC₅₀	0.19 μM Compound: Docetaxel	Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
MDA-MB-231	IC₅₀	0.07 μM Compound: Docetaxel	Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
MDA-MB-231	IC₅₀	0.01 μM Compound: Docetaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	0.02 μM Compound: Docetaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36786551]
MDA-MB-231	IC₅₀	1.98 μM Compound: Docetaxel	Antiproliferative activity against docetaxel-resistant human MDA-MB-231-DTR cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay Antiproliferative activity against docetaxel-resistant human MDA-MB-231-DTR cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay	[PMID: 36786551]
MDA-MB-231	IC₅₀	4.68 μM Compound: Docetaxel	Antiproliferative activity against docetaxel-resistant human MDA-MB-231-DTR cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against docetaxel-resistant human MDA-MB-231-DTR cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36786551]
MDA-MB-231	IC₅₀	0.17 μM Compound: PC	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 39102454]
MDA-MB-231	IC₅₀	38.9 μM Compound: Docetaxel	Cytotoxicity against human MDA-MB-231 cells assessed as cell death measured by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell death measured by MTT assay	[PMID: 39137365]
MDA-MB-468	IC₅₀	3.1 nM Compound: DT	Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
MES-SA	IC₅₀	3.4 nM Compound: DT	Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
MM1.S	IC₅₀	0.0118 μM Compound: Docetaxel	Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
MV4-11	GI₅₀	0.0005 μM Compound: Taxotere	Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by CellTiter-Glo luminescence assay Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by CellTiter-Glo luminescence assay	[PMID: 30802730]
MV4-11	GI₅₀	0.5 nM Compound: Taxotere	Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by CellTiter-Glo luminescence assay Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by CellTiter-Glo luminescence assay	[PMID: 30802730]
NCI/ADR-RES	IC₅₀	21.2 μM Compound: Docetaxel	Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay	[PMID: 27240278]
NCI/ADR-RES	IC₅₀	1530.5 nM Compound: Docetaxel	Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay	[PMID: 30036834]
NCI-H460	IC₅₀	0.89 μM Compound: Docetaxel	Cytostatic activity against human NCI-H460 cells Cytostatic activity against human NCI-H460 cells	[PMID: 30738653]
NCI-H460	IC₅₀	0.007 μM Compound: Docetaxel	Antiproliferative activity against human NCI-H460 cells Antiproliferative activity against human NCI-H460 cells	[PMID: 31005446]
NCI-H460	IC₅₀	0.004 μM Compound: Docetaxel	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
NCI-H460	IC₅₀	0.0024 μM Compound: Docetaxel	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
PC-3	IC₅₀	0.013 μM Compound: Docetaxel	Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 24 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 27077446]
PC-3	IC₅₀	5 nM Compound: Docetaxel	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 28462831]
PC-3	IC₅₀	8 nM Compound: Docetaxel	Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by trypan blue exclusion assay Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by trypan blue exclusion assay	[PMID: 28462831]
PC-3	IC₅₀	0.5 nM Compound: Docetaxel	Cytotoxicity against human PC3 cells after 72 hrs by MTS assay Cytotoxicity against human PC3 cells after 72 hrs by MTS assay	[PMID: 29406710]
PC-3	IC₅₀	0.0019 μM Compound: Docetaxel	Antiproliferative activity against docetaxel-sensitive human PC3 cells after 3 days by WST-1 assay Antiproliferative activity against docetaxel-sensitive human PC3 cells after 3 days by WST-1 assay	[PMID: 29784275]
PC-3	IC₅₀	0.6 nM Compound: Docetaxel	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 30629433]
PC-3	IC₅₀	0.5 nM Compound: Docetaxel	Antiproliferative activity against human PC3 cells Antiproliferative activity against human PC3 cells	[PMID: 31251599]
PC-3	GI₅₀	9 ng/mL Compound: Dxtl	Growth inhibition of human PC3 cells incubated for 48 hrs by MTS assay Growth inhibition of human PC3 cells incubated for 48 hrs by MTS assay	[PMID: 31767266]
PC-3	IC₅₀	0.0019 μM Compound: Docetaxel	Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay	[PMID: 33753258]
PC-3	IC₅₀	2.34 μM Compound: Docetaxel	Antiproliferative activity against Docetaxel-resistant human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay Antiproliferative activity against Docetaxel-resistant human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay	[PMID: 33753258]
PC-3	CC₅₀	1 nM Compound: Docetaxel	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34717125]
PC-3	CC₅₀	6.7 nM Compound: Docetaxel	Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay	[PMID: 34797052]
PC-3	IC₅₀	0.0006 μM Compound: Docetaxel	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay	[PMID: 36126331]
PC-3	IC₅₀	0.6 nM Compound: Docetaxel	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay	[PMID: 36126331]
PC-3	EC₅₀	7.6 nM Compound: Docetaxel	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability by MTT assay	[PMID: 37290495]
PC-3	IC₅₀	12.5 μM Compound: Docetaxel	Cytotoxicity against human PC-3 cells assessed as cell death measured by MTT assay Cytotoxicity against human PC-3 cells assessed as cell death measured by MTT assay	[PMID: 39137365]
PC-6	GI₅₀	1.48 ng/mL Compound: 162	Growth inhibition of human PC-6 cells Growth inhibition of human PC-6 cells	[PMID: 34213340]
RWPE-1	IC₅₀	1.73 μM Compound: Docetaxel	Cytotoxicity against human RWPE1 cells assessed as cell growth inhibition after 24 hrs by MTT assay Cytotoxicity against human RWPE1 cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 27077446]
SH-SY5Y	IC₅₀	0.0018 μM Compound: Docetaxel	Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured upto 72 hrs by clonogenic assay Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured upto 72 hrs by clonogenic assay	[PMID: 36126331]
SiHa	CC₅₀	0.22 μM Compound: Docetaxel	Cytotoxic activity in human SiHa cells by sulforhodamine B assay Cytotoxic activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
SiHa	IC₅₀	0.09 μM Compound: Docetaxel	Antiproliferative activity in human SiHa cells by sulforhodamine B assay Antiproliferative activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
SK-HEP1	IC₅₀	0.03 μM Compound: PC	Cytotoxicity against human SK-HEP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human SK-HEP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 39102454]
SK-MEL19	GI₅₀	0.002 μM Compound: Taxotere	Antiproliferative activity against human SK-MEL-19 cells incubated for 72 hrs by CellTiter-Glo luminescence assay Antiproliferative activity against human SK-MEL-19 cells incubated for 72 hrs by CellTiter-Glo luminescence assay	[PMID: 30802730]
SK-OV-3	IC₅₀	0.75 nM Compound: Taxotere	Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay	[PMID: 29517223]
SK-OV-3	IC₅₀	0.05 μM Compound: PC	Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 39102454]
SW-620	IC₅₀	0.02 μM Compound: DTX	Cytotoxicity against human SW-620 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SW-620 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32203786]
SW-620	IC₅₀	4.7 nM Compound: Docetaxel	Anticancer activity against human SW-620 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Anticancer activity against human SW-620 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33221063]
T84	IC₅₀	2.7 nM Compound: Docetaxel	Anticancer activity against human T84 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Anticancer activity against human T84 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33221063]
TERT-RPE1	IC₅₀	25 μM Compound: Docetaxel	Cytostatic activity against human hTERT-RPE1 cells Cytostatic activity against human hTERT-RPE1 cells	[PMID: 30738653]
TERT-RPE1	IC₅₀	0.0553 μM Compound: Docetaxel	Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis	[PMID: 33248847]
TERT-RPE1	IC₅₀	8.2 nM Compound: DT	Antiproliferative activity against human RPE-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human RPE-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
U-251	IC₅₀	0.7 nM Compound: Docetaxel	Antiproliferative activity against human U251MG cells after 72 hrs by MTT assay Antiproliferative activity against human U251MG cells after 72 hrs by MTT assay	[PMID: 30629433]
Vero	CC₅₀	1.3 μM Compound: Docetaxel	Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]
Vero	IC₅₀	0.13 μM Compound: Docetaxel	Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]
Z-138	IC₅₀	3 μM Compound: Docetaxel	Cytostatic activity against human Z138 cells Cytostatic activity against human Z138 cells	[PMID: 30738653]
Z-138	IC₅₀	0.009 μM Compound: Docetaxel	Antiproliferative activity against human Z138 cells Antiproliferative activity against human Z138 cells	[PMID: 31005446]
Z-138	IC₅₀	0.004 μM Compound: Docetaxel	Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
Z-138	IC₅₀	0.0142 μM Compound: Docetaxel	Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]

In Vitro

Docetaxel (0-1000 nM; 24-96 h) inhibits the growth of MCF7 and MDA-MB-231 cells, exhibiting biphasic sensitivity characteristics, with an IC₇₅ of approximately 2 nM in MDA-MB-231 and approximately 4 nM in MCF7^[5].
Docetaxel (2-100 nM; 8-48 h) induces subG1 hypodiploidy, whereas 100 nM induces G2/M mitotic arrest^[5].
Docetaxel (2 nM; 24 h) induces subdiploidy in MDA-MB-231, a process that requires passage through mitosis and is attenuated by MG132 (HY-13259), whereas 100 nM causes mitotic arrest^[5].
Docetaxel (4-100 nM; 24 h) induces abnormal mitosis with small mononuclei in MCF7 cells at 4 nM, whereas 100 nM induces multinucleated cells^[5].
Docetaxel (4-100 nM; 24 h) induces apoptosis in detached MCF7 cells primarily after mitotic arrest at 100 nM, whereas 4 nM leads to non-apoptotic/necrotic death^[5].
Docetaxel upregulates TNFRSF6/FAS in MCF7 and MDA-MB-231 cells in a concentration-independent manner; at 100 nM, it increases phosphorylation of p53, Bax, and Bcl-2, whereas 4 nM produces higher p21 in MCF7; the DNA damage marker phosphorylated H2AX is notably induced in MDA-MB-231^[5].
Docetaxel (2-100 nM) produces dose- and cell line-dependent transcriptional profiles in MCF7 and MDA-MB-231, involving p53 targets at 4 nM and mitosis/checkpoint genes at 100 nM^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[5]

Cell Line:

human breast carcinoma MCF7 and MDA-MB-231 cells
Concentration:

0, 1, 2, 10, 25, 50, 100, 500 nM (48 h viability)
0-1000 nM (24-96 h)
0.1, 0.5, 1, 5 nM (time-course)
4 nM and 100 nM (24 h morphology)
Incubation Time:

48 h (viability)
0, 25, 50, 75 h (time-course)
24 h (morphology)
Result:

Both cell lines showed a biphasic growth curve.
Below 10 nM docetaxel, there was a first slope of growth inhibition followed by recovery, then a second decay after 50 nM.
MDA-MB-231 cells showed higher growth inhibition at lower concentrations.
Low concentrations induced significant growth inhibition in both lines after 24 h.
At 100 nM, a high proportion of detached cells was observed after 24 h in both lines.
A concentration of 4 nM docetaxel did not induce the same pattern of cell detachment in MCF7 cells.

Cell Cycle Analysis^[5]

Cell Line:

MCF7 and MDA-MB-231 cells
Concentration:

4 nM and 100 nM (MCF7)
2 nM and 100 nM (MDA-MB-231)
Incubation Time:

8, 24, and 48 h
Result:

Exposed MCF7 and MDA‑MB‑231 breast cancer cells to docetaxel and observed concentration‑dependent subG1 accumulation: low nanomolar doses (1‑4 nM) induced prominent time‑dependent subG1/hypodiploid populations, whereas 100 nM docetaxel triggered >80 % G2/M arrest with minimal subG1 signals.

Apoptosis Analysis^[5]

Cell Line:

MCF7 cells
Concentration:

4 nM and 100 nM
Incubation Time:

24 h
Result:

Exposed MCF7 cells to docetaxel and quantified Annexin‑V/PI cell‑death signals; 4 nM docetaxel induced lower early‑apoptosis fraction but predominant Annexin‑V‑PI double‑positive necrotic population, whereas 100 nM docetaxel triggered higher early‑apoptosis rates with abundant detached dying cells.
Observed rising double‑positive necrotic cells over extended incubation under 4 nM docetaxel, verifying non‑apoptotic cell‑death phenotype.

Cell Cycle Analysis^[5]

Cell Line:

MDA-MB-231 cells
Concentration:

2 nM (24 h)
10 mM MG132 (combination)
Incubation Time:

24 h
Result:

Induced subdiploidy in MDA-MB-231, a process that requires passage through mitosis and is attenuated by MG132 (HY-13259), whereas 100 nM causes mitotic arrest.

Immunofluorescence^[5]

Cell Line:

MCF7 cells
Concentration:

4 nM and 100 nM
Incubation Time:

24 h
Result:

Induced abnormal mitosis with small mononuclei in MCF7 cells at 4 nM, whereas 100 nM induces multinucleated cells.

In Vivo

Docetaxel (DTX) (oral granule formulation; 25‑50 mg/kg; repeated once-daily administration) exhibits sex-dependent maximum tolerated dose and differential tissue distribution characteristics in FVB mice; high doses can cause kidney injury^[1].
Docetaxel (15-150 mg/kg; single bolus) in Sprague-Dawley rats, intraperitoneal administration compared with intravenous administration significantly increases peritoneal fluid drug exposure, reduces systemic plasma exposure, and alters drug accumulation levels in multiple peritoneal organs^[3].
Docetaxel (DTX) (10 mg/kg; single intraperitoneal injection; 4 days) decreases SOD activity and increases CAT activity in rat liver tissue^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 114977-28-5
Appearance Solid
Masse moléculaire 807.88
Formule C₄₃H₅₃NO₁₄
Color White to off-white
SMILES

O=C(OC(C)(C)C)N[C@@H](C1=CC=CC=C1)[C@H](C(O[C@@H]2C(C)=C([C@@H](O)C([C@@]3(C)[C@]([C@@](CO4)(OC(C)=O)[C@@]4([H])C[C@@H]3O)([H])[C@@H]5OC(C6=CC=CC=C6)=O)=O)C(C)(C)[C@@]5(O)C2)=O)O
Synonyms

RP-56976
Structure Classification
- Terpenoids
- Diterpenoids
Initial Source
- Endogenous metabolite
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Publications (183)

All Apoptosis AnalysisWBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Targeting oncogenic TβRI signaling inhibits androgen-independent prostate cancer growth and metastasis. [Abstract]

2026 Jun 17;11(1):238. PMID: 42303991
Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Signal Transduct Target Ther

Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation. [Abstract]

2022 Sep 12;7(1):317. PMID: 36097006
J Hematol Oncol

Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis. [Abstract]

2023 May 3;16(1):46. PMID: 37138326

Docetaxel purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2023 May 3;16(1):46. [Abstract]

Under docetaxel treatment (0.5 nM, 1 nM, 2.5 nM, 5 nM, 10 nM, 20 nM, 48 hours), myeloid-like tumor hybrid cells were less sensitive than the RM1 cell line.
J Clin Oncol

2026 Mar 2.
Mol Cancer

2026 May 13.
Mol Cancer

Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy. [Abstract]

2024 May 9;23(1):83. PMID: 38730475
Cancer Discov

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer. [Abstract]

2026 Jun 22. PMID: 42329102
Adv Mater

Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local Adhesion and Drug Release to Bladder Cancers. [Abstract]

2025 Jul 4:e2505231. PMID: 40611758
Eur Urol

Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. [Abstract]

2021 Jun;79(6):722-733. PMID: 33153817
Cancer Res

Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer. [Abstract]

2025 Oct 9. PMID: 41066596
Adv Funct Mater

2023 Dec 15.
ACS Nano

Metabolic Control by Heat Stress Determining Cell Fate to Ferroptosis for Effective Cancer Therapy. [Abstract]

2021 Apr 27;15(4):7179-7194. PMID: 33861924
Redox Biol

2026 Sep 2:97:104376. PMID: 42700475
Sci Transl Med

TSPAN8+ myofibroblastic cancer-associated fibroblasts promote chemoresistance in patients with breast cancer. [Abstract]

2024 Apr 3;16(741):eadj5705. PMID: 38569015

Docetaxel purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2024 Apr 3;16(741):eadj5705. [Abstract]

Growth inhibition by docetaxel (Doc) (0–10 μM) in TS− or TS+ CAFs isolated from patients with BC was observed. The survival rates of TSPAN8+ CAFs were enhanced compared with TSPAN8− CAFs when challenged with an equal dosage of docetaxel.
Biomark Res

circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3. [Abstract]

2022 Jul 13;10(1):48. PMID: 35831872
Acta Pharm Sin B

Intracellular aggregation of peptide-reprogrammed small molecule nanoassemblies enhances cancer chemotherapy and combinatorial immunotherapy. [Abstract]

2021 Apr;11(4):1069-1082. PMID: 33996418
J Clin Invest

Targeting Wnt/β-Catenin and circadian regulator restores PRC2/EZH2 controlled chromatin bivalency and suppresses cell state diversity. [Abstract]

2026 Mar 17:e200260. PMID: 41842971
J Exp Clin Cancer Res

LncRNA SNHG4 promotes prostate cancer cell survival and resistance to enzalutamide through a let-7a/RREB1 positive feedback loop and a ceRNA network. [Abstract]

2023 Aug 18;42(1):209. PMID: 37596700
Adv Sci (Weinh)

Red Blood Cells Internalize Extracellular DNA via Apoptotic Bodies with Clinical Relevance to Cancer Patients. [Abstract]

2026 Mar;13(13):e11408. PMID: 41486873
Adv Sci (Weinh)

Osteoblast-Derived ECM1 Promotes Anti-Androgen Resistance in Bone Metastatic Prostate Cancer. [Abstract]

2025 Jan;12(2):e2407662. PMID: 39563492

Docetaxel purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jan;12(2):e2407662. [Abstract]

Representative images and quantitative analysis of surviving clones after treatment of C4-2B and LNCaP cells with PBS or ECM1 protein (200 ng/mL) in the presence of docetaxel (10 μM) were shown.

Docetaxel purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jan;12(2):e2407662. [Abstract]

Flow cytometry analysis showed representative images and quantification of apoptosis in C4-2B and LNCaP cells in the presence of docetaxel (10 μM). Docetaxel caused PCa cell apoptosis compared to that in the vehicle group.
Cell Rep Med

Sex-biased intratumoral microbiome influences tumor molecular and immune landscape and disease outcomes. [Abstract]

2026 May 19;7(5):102757. PMID: 42013847
Cell Rep Med

A human patient-derived organoid biobank to model tumor heterogeneity and therapeutic vulnerability for oral squamous cell carcinoma. [Abstract]

2026 Feb 17;7(2):102622. PMID: 41707653
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 15;6(4):102053. PMID: 40187357
Cell Rep Med

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. [Abstract]

2023 Feb 21;4(2):100911. PMID: 36657446
Biomaterials

Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer. [Abstract]

2022 Oct:289:121783. PMID: 36084486
J Transl Int Med

Anti-SIA-cIgG enhances chemotherapy effectiveness through PTPN13-regulated tumor stemness in head and neck squamous cell carcinoma. [Abstract]

2026 Mar 26;14(2):237-258. PMID: 42046805
J Control Release

Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment. [Abstract]

2024 Dec:376:829-841. PMID: 39491626
J Control Release

Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer. [Abstract]

2023 Jan:353:490-506. PMID: 36460179
J Control Release

Management of lymph node metastasis via local chemotherapy can prevent distant metastasis and improve survival in mice. [Abstract]

2021 Jan 10:329:847-857. PMID: 33065097
Cell Death Dis

PMEPA1 modulates YAP1 nuclear translocation to disrupt EMT subtypes and promote metastasis in Biliary tract cancer. [Abstract]

2026 Apr 3;17(1):449. PMID: 41932868
Cell Death Dis

AKT1 phosphorylates PRMT7 to promote GLUD1 methylation and gastric cancer progression. [Abstract]

2026 Mar 24;17(1):363. PMID: 41876450
Cell Death Dis

Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]

2025 Mar 12;16(1):170. PMID: 40075071
Cell Death Dis

Single-cell transcriptome profiles the heterogeneity of tumor cells and microenvironments for different pathological endometrial cancer and identifies specific sensitive drugs. [Abstract]

2024 Aug 7;15(8):571. PMID: 39112478
Pharmacol Res

Time-dependent proteomics and drug response in expanding cancer cells. [Abstract]

2024 Jun:204:107208. PMID: 38729587
Cancer Lett

Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications. [Abstract]

2025 Feb 1:610:217339. PMID: 39608442
Cancer Lett

The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs. [Abstract]

2023 Sep 1:571:216338. PMID: 37549770
J Immunother Cancer

ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer. [Abstract]

2021 Jul;9(7):e001758. PMID: 34301812
Phytomedicine

Artemisitene induces apoptosis of breast cancer cells by targeting FDFT1 and inhibits the growth of breast cancer patient-derived organoids. [Abstract]

2024 Dec:135:156155. PMID: 39461203
Phytomedicine

Sculponeatin A promotes the ETS1-SYVN1 interaction to induce SLC7A11/xCT-dependent ferroptosis in breast cancer. [Abstract]

2023 Aug:117:154921. PMID: 37327642
Phytomedicine

Compound K is a potential clinical anticancer agent in prostate cancer by arresting cell cycle. [Abstract]

2023 Jan:109:154584. PMID: 36610114
Phytomedicine

Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity to hinder tumor growth and metastasis in prostate cancer through EGFR/JAK1/STAT3 pathway to inhibit PD-1/PD-L1 checkpoint signaling. [Abstract]

2022 May:99:153939. PMID: 35172257
Mater Today Bio

Mannosylated graphene oxide nanotherapeutics co-delivering docetaxel and a STING agonist reprogram myeloid cells and potentiate antitumor immunity. [Abstract]

2026 Mar 31:38:103086. PMID: 42006712
ACS Sens

Cryopreservable Through-Hole Arrays for the High-Throughput Three-Dimensional Smartphone-Based Cell Colorimetric Assay. [Abstract]

2023 Feb 24;8(2):543-554. PMID: 36705290
Genome Med

Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy. [Abstract]

2024 Jan 12;16(1):11. PMID: 38217005
Cell Death Discov

2026 Jul 8. PMID: 42420245
J Transl Med

2026 Jul 11. PMID: 42436511
J Colloid Interface Sci

Smart dual responsive nanocarriers with reactive oxygen species amplification assisted synergistic chemotherapy against prostate cancer. [Abstract]

2022 May 2;622:789-803. PMID: 35544966
Proc Natl Acad Sci U S A

Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling. [Abstract]

2023 Apr 25;120(17):e2218522120. PMID: 37068243
Diabetes

FGF13-sensitive alteration of Parkin safeguards mitochondrial homeostasis in endothelium of diabetic nephropathy. [Abstract]

2023 Jan 1;72(1):97-111. PMID: 36256844
Oncogene

HOMER3 drives oral squamous cell carcinoma progression through TRPV6 calcium influx and TUBB3 microtubule stabilization. [Abstract]

2026 Jan;45(2):278-294. PMID: 41326663
Oncogene

Targeting SREBP-dependent lipogenesis potentiates the anti-tumor activity of docetaxel by increasing membrane permeability and intracellular drug accumulation. [Abstract]

2025 Nov;44(45):4405-4412. PMID: 41046255
Int J Mol Med

Paeoniflorigenone inhibits ovarian cancer metastasis through targeting the MUC1/Wnt/β‑catenin pathway. [Abstract]

2024 Jul;54(1):60. PMID: 38785138
Arch Pharm Res

Modulating versatile pathways using a cleavable PEG shell and EGFR-targeted nanoparticles to deliver CRISPR-Cas9 and docetaxel for triple-negative breast cancer inhibition. [Abstract]

2024 Nov;47(10-11):829-853. PMID: 39482441
Biofabrication

3D bioprinting of multi-cellular tumor microenvironment for prostate cancer metastasis. [Abstract]

2023 Jun 9;15(3). PMID: 37236173
Cell Mol Gastroenterol Hepatol

Fibrinogen/AKT/Microfilament Axis Promotes Colitis by Enhancing Vascular Permeability. [Abstract]

2021;11(3):683-696. PMID: 33075564
Free Radic Biol Med

Targeted delivery of nebivolol via lactoferrin-modified liposomes inhibits NEK7-mediated pyroptosis to ameliorate inflammatory bowel disease. [Abstract]

2026 Aug 16:252:493-508. PMID: 42061481
Clin Transl Med

2026 Jul;16(7):e70737. PMID: 42415249
Cancer Immunol Res

Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity. [Abstract]

2023 May 3;11(5):583-599. PMID: 36921097
ACS Appl Mater Interfaces

Single-Cell Fluidic Force Spectroscopy Reveals Dynamic Mechanical Fingerprints of Malignancy in Breast Cancer. [Abstract]

2024 Sep 25;16(38):50147-50159. PMID: 39105773
ACS Appl Mater Interfaces

Glutathione and Esterase Dual-Responsive Smart Nano-drug Delivery System Capable of Breaking the Redox Balance for Enhanced Tumor Therapy. [Abstract]

2023 May 3;15(17):20697-20711. PMID: 37083309
Cell Rep

Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis. [Abstract]

2024 Jul 3;43(7):114431. PMID: 38968071
Br J Pharmacol

A vitamin D-based strategy overcomes chemoresistance in prostate cancer. [Abstract]

2024 Nov;181(21):4279-4293. PMID: 38982588
Cancer Cell Int

Organoids as a model system for researching human neuroendocrine tumor of the breast. [Abstract]

2024 Dec 27;24(1):433. PMID: 39731167
Cancer Cell Int

Activation of the PERK/eIF2α axis is a pivotal prerequisite of taxanes to cancer cell apoptosis and renders synergism to overcome paclitaxel resistance in breast cancer cells. [Abstract]

2024 Jul 17;24(1):249. PMID: 39020371
Drug Deliv Transl Res

Surface-engineered nanostructured lipid carrier systems for synergistic combination oncotherapy of non-small cell lung cancer. [Abstract]

2021 Oct;11(5):2030-2051. PMID: 33215254
J Agric Food Chem

Eurochevalierines A - I, Sesquiterpene Alkaloid Hybrids with Anti-Triple Negative Breast Cancer Activity from Penicillium sp. HZ-5. [Abstract]

2024 Jul 31;72(30):16801-16811. PMID: 39016690
Eur J Med Chem

Jatrophane diterpenoids from Euphorbia sororia as potent modulators against P-glycoprotein-based multidrug resistance. [Abstract]

2018 Feb 25:146:157-170. PMID: 29407947
Cell Biosci

Modulation of cell cycle increases CRISPR-mediated homology-directed DNA repair. [Abstract]

2023 Nov 25;13(1):215. PMID: 38007480
Biochem Pharmacol

Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells. [Abstract]

2020 May;175:113865. PMID: 32142727
Life Sci

A protective role of ECSIT in chemotherapy-induced intestinal mucositis by maintaining Lgr5+ intestinal stem cells and gut homeostasis. [Abstract]

2026 Mar 15:389:124236. PMID: 41611204
Life Sci

N6-methyladenosine-modified circQKI inhibits prostate cancer docetaxel-sensitivity via miR-188-3p/Beclin-1 pathway. [Abstract]

2025 Jul 1:372:123646. PMID: 40250752
Life Sci

Rational design, engineer, and characterization of a novel pegylated single isomer human arginase for arginine depriving anti-cancer treatment. [Abstract]

2021 Jan 1:264:118674. PMID: 33129876
Life Sci

Arctigenin inhibits proliferation of ER-positive breast cancer cells through cell cycle arrest mediated by GSK3-dependent cyclin D1 degradation. [Abstract]

2020 Sep 1:256:117983. PMID: 32565252
Breast Cancer Res

TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9. [Abstract]

2024 Mar 19;26(1):48. PMID: 38504374
Oncogenesis

2026 Sep 28.
Oncogenesis

2026 Aug 20.
Int J Pharm

Surface-modified nanoparticles of docetaxel for chemotherapy of lung cancer: an intravenous to oral switch. [Abstract]

2023 Apr 5:636:122846. PMID: 36921744
Commun Biol

A compatible gravity-driven organoid perfusion (GDOP) platform for drug screening with sensitivity and toxicity process evaluation. [Abstract]

2026 Apr 2;9(1):718. PMID: 41922471
Cancer Immunol Immunother

Construction and application of a humanized mouse model for prostate cancer in immunotherapy. [Abstract]

2025 Nov 18;74(12):377. PMID: 41251708
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Cancer Biol Ther

Suppression of LncRNA AC008406.3 sensitizes breast cancer cells to docetaxel via triggering cuproptosis. [Abstract]

2026 Dec 31;27(1):2676474. PMID: 42189063
Clin Epigenetics

Investigating the mechanisms by which low NAT1 expression in tumor cells contributes to chemo-resistance in colorectal cancer. [Abstract]

2025 May 6;17(1):77. PMID: 40329330
Pharmaceuticals (Basel)

Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis. [Abstract]

2024 Apr 29;17(5):569. PMID: 38794139
Int J Mol Sci

Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations. [Abstract]

2022 Nov 19;23(22):14385. PMID: 36430869
Int J Mol Sci

Potent Anti-Cancer Properties of Phthalimide-Based Curcumin Derivatives on Prostate Tumor Cells. [Abstract]

2018 Dec 21;20(1):28. PMID: 30577600
Biol Direct

Integrative genomics unveils basement membrane-related diagnostic markers and therapeutic targets in esophageal squamous cell carcinoma. [Abstract]

2024 Sep 11;19(1):79. PMID: 39256753
J Enzyme Inhib Med Chem

Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer. [Abstract]

2026 Dec;41(1):2622725. PMID: 41665114
Microchem J

2025 Oct 15;218:115702.
ACS Omega

Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. [Abstract]

2024 Feb 28;9(10):11870-11882. PMID: 38496939
Chem Biol Interact

The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-induced apoptosis in breast invasive carcinoma: A pan-cancer analysis. [Abstract]

2023 Mar 1:373:110372. PMID: 36736488
J Mol Med (Berl)

Tyrosine hydroxylase as a therapeutic target: insights from adrenergic nerve and TNBC cell interactions. [Abstract]

2026 Mar 19;104(1):53. PMID: 41857421
Mol Med Rep

miR‑133b affects cell proliferation, invasion and chemosensitivity in renal cell carcinoma by inhibiting the ERK signaling pathway. [Abstract]

2020 Jul;22(1):67-76. PMID: 32377748
Sci Rep

2026 Aug 29.
Sci Rep

Ring-finger protein RNF126 promotes prostate cancer progression via regulation of MBNL1. [Abstract]

2025 Jul 4;15(1):23847. PMID: 40615482
Int J Cancer

Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]

2024 Jul 15;155(2):324-338. PMID: 38533706
Sci Rep

Monolayer culture alters EGFR inhibitor response through abrogation of microRNA-mediated feedback regulation. [Abstract]

2024 Mar 27;14(1):7303. PMID: 38538642
Cancer Sci

NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway. [Abstract]

2024 Feb;115(2):412-426. PMID: 38115797
Transl Oncol

MiR-138-5p inhibits prostate cancer cell proliferation and chemoresistance by targeting APOBEC3B. [Abstract]

2023 Sep:35:101723. PMID: 37364333
Sci Rep

Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening. [Abstract]

2023 Jun 3;13(1):9043. PMID: 37270558
Eur J Med Res

Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer. [Abstract]

2025 Aug 4;30(1):704. PMID: 40760677
Cancers (Basel)

Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer. [Abstract]

2020 Jul 28;12(8):2092. PMID: 32731472
J Cell Mol Med

Anticancer Activity of Annonacin and Its Synergistic Enhancement of Docetaxel Efficacy in Prostate Cancer. [Abstract]

2025 Dec;29(23):e70972. PMID: 41328625
J Pharm Investig

2025 Sep 19.
J Cell Mol Med

Telmisartan anti-cancer activities mechanism through targeting N-cadherin by mimicking ADH-1 function. [Abstract]

2022 Apr;26(8):2392-2403. PMID: 35224849
J Liposome Res

Fabrication, optimization, and in vitro evaluation of docetaxel-loaded nanostructured lipid carriers for improved anticancer activity. [Abstract]

2020 Jun;30(2):182-196. PMID: 31060404
Mol Oncol

Patient therapy outcome modeling in cancer organoids is improved by cancer-associated fibroblasts and organoid assembly convolution. [Abstract]

2026 Jun 5. PMID: 42246237
iScience

Identifying CTSF and GSTM3 as chemoresistance therapeutic targets in breast cancer through multi-omics MR analysis. [Abstract]

2025 Oct 30;28(12):113908. PMID: 41321627
iScience

ALKBH5-IGF2BP2 axis mediates prostate cancer progression and docetaxel resistance via m6A-stabilized CLSPN RNA. [Abstract]

2025 Sep 9;28(10):113520. PMID: 41069850
Biochim Biophys Acta Mol Cell Res

Cancer-associated fibroblasts secreting IL-6 inhibit the cisplatin and docetaxel killing effect in lung squamous cell carcinoma. [Abstract]

2025 Jul 31;1872(8):120029. PMID: 40752594
FEBS J

ABCB1-mediated docetaxel resistance reversed by erastin in prostate cancer. [Abstract]

2024 Jul;291(14):3249-3266. PMID: 38712529
Pharm Res

Active Targeting of Colorectal Cancer Using Chemotherapy-Loaded Nanoparticles Functionalized with a Folate Receptor-α (FRα) Ligand, Pemetrexed. [Abstract]

2025 Nov 18. PMID: 41254319
BJU Int

Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer. [Abstract]

2025 Nov 3. PMID: 41178321
BMC Cancer

Platycodin D-mediated METTL16 downregulation promotes docetaxel treatment of prostate cancer by regulating ferroptosis. [Abstract]

2025 Jul 1;25(1):1042. PMID: 40597047
Front Biosci (Landmark Ed)

Hypoxia-Induced VGF Promotes Cell Migration and Invasion in Prostate Cancer via the PI3K/Akt Axis. [Abstract]

2025 Feb 20;30(2):25522. PMID: 40018933
J Biol Chem

Androgen receptor splicing variant 7 (ARV7) inhibits docetaxel sensitivity by inactivating the spindle assembly checkpoint. [Abstract]

2021 Jan-Jun:296:100276. PMID: 33428943
PLoS Genet

Generation of prostate cancer assembloids modeling the patient-specific tumor microenvironment. [Abstract]

2025 Mar 31;21(3):e1011652. PMID: 40163511
Int J Med Sci

Integrative analysis identifies PIGK as an oncogenic glycosylphosphatidylinositol transamidase subunit with prognostic, immunological, and therapeutic relevance in head and neck cancer. [Abstract]

2026 Jan 1;23(1):161-176. PMID: 41399371
Pathol Res Pract

Alendronate-functionalized ZIF-8 nanoplatform for targeted delivery of SHH siRNA and docetaxel to treat prostate cancer bone metastasis. [Abstract]

2025 Sep:273:156138. PMID: 40694986
Breast Cancer

Quercetin Promote the Chemosensitivity in Organoids Derived from Patients with Breast Cancer. [Abstract]

2024 Dec 20:16:993-1004. PMID: 39720358
Materials

Antitumor Efficacy of Focused Ultrasound-MFL Nanoparticles Combination Therapy in Mouse Breast Cancer Xenografts. [Abstract]

2020 Mar 2;13(5):1099. PMID: 32121631
Micromachines

Integrated Experimental-Computational Framework for Drug Transport Quantification in 3D Microtissues™. [Abstract]

2026 Mar 9;17(3):332. PMID: 41900218
Mol Carcinog

ZNF480 Accelerates Chemotherapy Resistance in Breast Cancer by Competing With TRIM28 and Stabilizing LSD1 to Upregulate the AKT-GSK3β-Snail Pathway. [Abstract]

2025 Jan;64(1):192-208. PMID: 39503216
Arch Biochem Biophys

KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylation. [Abstract]

2023 Mar 15:737:109551. PMID: 36822388

Docetaxel purchased from MedChemExpress. Usage Cited in: Arch Biochem Biophys. 2023 Mar 15:737:109551. [Abstract]

Docetaxel (30 nM) exhibits anti-tumor activity in parental (DU145 and PC-3) and docetaxel-resistant (DU145/DTX50 and PC-3/DTX30) cell lines by down-regulating KIF14 expression.
Reprod Toxicol

Protective effects of rutin against docetaxel-induced testicular damage in rats: Effects on antioxidant defence, apoptosis and autophagy. [Abstract]

2026 Jan:139:109110. PMID: 41248718
Transl Lung Cancer Res

Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation. [Abstract]

2024 Oct 31;13(10):2698-2712. PMID: 39507032
Front Oncol

Erastin Reverses ABCB1-Mediated Docetaxel Resistance in Ovarian Cancer. [Abstract]

2019 Dec 19:9:1398. PMID: 31921655
Chem Biol Drug Des

Polyphyllin VII Enhances the Sensitivity of Prostate Cancer Cells to Docetaxel by Promoting Mitochondrial Dysfunction and Inducing Ferroptosis. [Abstract]

2025 Feb;105(2):e70053. PMID: 39871642
Biochem Biophys Rep

Peroxiredoxin-1 as a molecular chaperone that regulates glutathione S-transferase P1 activity and drives mutidrug resistance in ovarian cancer cells. [Abstract]

2024 Jan 14:37:101639. PMID: 38288281
Breast Cancer Res Treat

Organoid models derived from patients with malignant phyllodes tumor of the breast. [Abstract]

2023 Jul;200(2):193-201. PMID: 37204665
J Cancer Res Clin Oncol

Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs. [Abstract]

2022 Dec;148(12):3511-3520. PMID: 35962287
J Therm Biol

2026 Sep 28:141:104576. PMID: 42828942
J Appl Polym Sci

18 February 2022.
J Microencapsul

Fabrication, optimisation and in vitro evaluation of docetaxel and curcumin Co-loaded nanostructured lipid carriers for improved antitumor activity against non-small cell lung carcinoma. [Abstract]

2020 Dec;37(8):543-556. PMID: 32924677
J Microencapsul

Docetaxel-loaded PAMAM-based poly (γ-benzyl-l-glutamate)-b-d-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles in human breast cancer and human cervical cancer therapy. [Abstract]

2019 Sep;36(6):552-565. PMID: 31403342
Pharm Dev Technol

Dual-modified PCL-PEG nanoparticles for improved targeting and therapeutic efficacy of docetaxel against colorectal cancer. [Abstract]

2021 Oct;26(8):910-921. PMID: 34280065
Int J Immunopathol Pharmacol

2026 Jan-Dec:40:3946320261474427. PMID: 42536653
PLoS One

RIPK2 induces docetaxel resistance in prostate cancer through the NF-κB/P-gp signaling pathway. [Abstract]

2026 Jan 21;21(1):e0341445. PMID: 41563982
Discov Oncol

Targeting XPO6 inhibits prostate cancer progression and enhances the suppressive efficacy of docetaxel. [Abstract]

2023 May 27;14(1):82. PMID: 37243787
Clin Transl Oncol

Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism. [Abstract]

2022 Nov;24(11):2231-2240. PMID: 35852680
Biochem Biophys Res Commun

2026 Sep 24:832:154364. PMID: 42542043
Biochem Biophys Res Commun

Vindoline, a vinca alkaloid derived from Catharanthus roseus, targets ABCB1 to overcome docetaxel resistance in prostate cancer. [Abstract]

2026 Jun 18:818:153767. PMID: 42000630
Oncol Lett

PP2A promotes apoptosis and facilitates docetaxel sensitivity via the PP2A/p-eIF4B/XIAP signaling pathway in prostate cancer. [Abstract]

2022 Mar;23(3):101. PMID: 35154432
Anticancer Drugs

Exosomal circRNA Scm-like with four malignant brain tumor domains 2 (circ-SFMBT2) enhances the docetaxel resistance of prostate cancer via the microRNA-136-5p/tribbles homolog 1 pathway. [Abstract]

2022 Oct 1;33(9):871-882. PMID: 36136987
Eur J Histochem

Docetaxel-resistant triple-negative breast cancer cell-derived exosomal lncRNA LINC00667 reduces the chemosensitivity of breast cancer cells to docetaxel via targeting miR-200b-3p/Bcl-2 axis. [Abstract]

2022 Oct 25;66(4). PMID: 36281649
Biomed Chromatogr

Investigation of the apoptosis-inducing effect of docetaxel by comprehensive LC-MS-based metabolomics and network pharmacology approaches. [Abstract]

2022 Sep;36(9):e5417. PMID: 35633112
Mol Biol Res Commun

Combinatorial effects of telmisartan and docetaxel on cell viability and metastatic gene expression in human prostate and breast cancer cells. [Abstract]

2022 Mar;11(1):11-20. PMID: 35463822
Int J Clin Exp Pathol

2017;10(3):3033-3042.
Adv Urol

2026 Apr 15;2026(1):7448726.
Biomed Pharmacother

2026 Sep:202:119803. PMID: 42537395
Preprints

2026 Mar 3.
bioRxiv

2026 Mar 27.
bioRxiv

2026 Mar 18.
bioRxiv

Loss of PIK3CA allows in vitro growth but not in vivo progression of KRAS mutant lung adenocarcinoma in a syngeneic orthotopic implantation model. [Abstract]

2026 Feb 4:2026.02.02.701385. PMID: 41676515
SSRN

2025 Dec 26.
Res Sq

2025 Sep 7.
bioRxiv

2025 Sep 21.
University of Granada

2025.
SSRN

2025 Jun 4.
bioRxiv

2025 June 01.
Res Sq

Novel mixed cancer-cell models designed to capture inter-patient tumor heterogeneity for accurate evaluation of drug combinations. [Abstract]

2025 May 16:rs.3.rs-6590535. PMID: 40470249
University of Granada

2025.
University of Beirut

2025.
bioRxiv

Diverse microtubule-destabilizing drugs induce equivalent molecular pathway responses in endothelial cells. [Abstract]

2025 Jan 24:2025.01.22.632572. PMID: 39896568
University of Minnesota

2024.
SSRN

2024 Mar 22.
bioRxiv

Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles. [Abstract]

2023 Nov 1:2023.10.29.564598. PMID: 37961545
Biomed Pharmacother

Dual receptor specific nanoparticles targeting EGFR and PD-L1 for enhanced delivery of docetaxel in cancer therapy. [Abstract]

2023 Sep:165:115023. PMID: 37329708
Preprints

2023 Jul 13.
Biomed Pharmacother

Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. [Abstract]

2023 Jul:163:114751. PMID: 37105073
University of Adelaide

2023 Jan.
Patent

US20230145200A1.
Research Square Print

November 29th, 2022.
Research Square Print

November 29th, 2022.
Oxid Med Cell Longev

Ferroptosis Induction Improves the Sensitivity of Docetaxel in Prostate Cancer. [Abstract]

2022 May 24:2022:4930643. PMID: 39282153
J Oncol

Solamargine Inhibits Prostate Cancer Cell Growth and Enhances the Therapeutic Efficacy of Docetaxel via Akt Signaling. [Abstract]

2022 Mar 10:2022:9055954. PMID: 35310915
Seoul National University

Molecular medicine and Biopharmaceutical sciences. 2021 Dec.
Mater Sci Eng C Mater Biol Appl

Reactive oxygen species and glutathione dual responsive nanoparticles for enhanced prostate cancer therapy. [Abstract]

2021 Apr:123:111956. PMID: 33812584
Research Square Preprint

2021 Jan.
Nanotheranostics

Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo. [Abstract]

2021 Jan 1;5(2):143-154. PMID: 33457193
Nanotheranostics

Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo. [Abstract]

2021 Jan 1;5(2):143-154. PMID: 33457193
Oncotarget

Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease. [Abstract]

2017 Dec 2;8(68):112313-112329. PMID: 29348827
Oncotarget

Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer. [Abstract]

2016 May 17;7(20):28891-902. PMID: 27049720

Docetaxel purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 May 17;7(20):28891-902. [Abstract]

Western blot analyses for Brachyury and AR expression in prostate cell lines treated with Docetaxel (Doc) or with XRP6258 (Cab). Graphs represent the densimetric semi-quantification of western blot images.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (123.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 50 mg/mL (61.89 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2378 mL

6.1890 mL

12.3781 mL

5 mM

0.2476 mL

1.2378 mL

2.4756 mL

10 mM

0.1238 mL

0.6189 mL

1.2378 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (6.19 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 5 mg/mL (6.19 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (2.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 4

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (2.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 5

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (2.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (290 KB)
SDS (558 KB)
- English - EN (558 KB)
- Français - FR (558 KB)
- Deutsch - DE (558 KB)
- Norwegian - NO (558 KB)
- Español - ES (558 KB)
- Swedish - SV (558 KB)
- Italian - IT (558 KB)
- Korean - KR (558 KB)
- Portuguese - PT (558 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Dong X, et al. Maximum tolerated dose and toxicity evaluation of orally administered docetaxel granule in mice. Toxicology reports. 2024 Jun;12:430-435.

[2]. Pieniążek A, et al. Oxidative stress induced in rat liver by anticancer drugs doxorubicin, paclitaxel and docetaxel. Advances in medical sciences. 2013;58(1):104-11.

[3]. Marchettini P, et al. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer chemotherapy and pharmacology. 2002 Jun;49(6):499-503.

[4]. Clarke SJ, et al. Clinical pharmacokinetics of docetaxel. Clinical pharmacokinetics. 1999 Feb;36(2):99-114.

[5]. Hernández-Vargas H, et al. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene. 2007 May 03;26(20):2902-13.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	1.2378 mL	6.1890 mL	12.3781 mL	30.9452 mL
	5 mM	0.2476 mL	1.2378 mL	2.4756 mL	6.1890 mL
	10 mM	0.1238 mL	0.6189 mL	1.2378 mL	3.0945 mL
	15 mM	0.0825 mL	0.4126 mL	0.8252 mL	2.0630 mL
	20 mM	0.0619 mL	0.3095 mL	0.6189 mL	1.5473 mL
	25 mM	0.0495 mL	0.2476 mL	0.4951 mL	1.2378 mL
	30 mM	0.0413 mL	0.2063 mL	0.4126 mL	1.0315 mL
	40 mM	0.0309 mL	0.1547 mL	0.3095 mL	0.7736 mL
	50 mM	0.0248 mL	0.1238 mL	0.2476 mL	0.6189 mL
	60 mM	0.0206 mL	0.1032 mL	0.2063 mL	0.5158 mL
DMSO	80 mM	0.0155 mL	0.0774 mL	0.1547 mL	0.3868 mL
DMSO	100 mM	0.0124 mL	0.0619 mL	0.1238 mL	0.3095 mL

Bioz

Docetaxel

183 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Docetaxel

Publications Citing Use of MedChemExpress (MCE) Docetaxel

Voir tous les produits spécifiques à Isoform Cytochrome P450